Carbohydrate Storage Diseases
docx
keyboard_arrow_up
School
VORONEZH STATE TECHNICAL UNIVERSITY *
*We aren’t endorsed by this school
Course
1003
Subject
Health Science
Date
Nov 24, 2024
Type
docx
Pages
5
Uploaded by SargentMorning2861
1
Carbohydrate Storage Diseases
Name
Institution
Course
Instructor
Date
2
Carbohydrate Storage Diseases
A group of rare inherited metabolic conditions called "carbohydrate storage disorders"
reduces the body's efficient glycogen storage and utilization. Glycogen is the body's principal
source of glucose storage and is crucial for steady blood sugar levels. If this mechanism fails, it
can cause a wide range of potentially fatal conditions. This article focuses on the molecular
underpinnings of two prevalent carbohydrate storage disorders, Glycogen Storage Disease Type I
(GSD-I) and Glycogen Storage Disease Type II (GSD-II), often known as Pompe disease. The
aims of pharmacological treatment and therapeutic methods to these disorders will also be
examined in this study.
Carbohydrate Storage Diseases
Insufficiencies in the enzymes involved in the metabolism of glycogen are characteristic
of disorders involving the storage of carbohydrates. The clinical manifestations of these diseases
stem from impaired glycogen generation, breakdown, or transport.
1
One of the most common
disorders affecting how the body stores carbohydrates is called Von Gierke disease, or Glycogen
Storage Disease Type I (GSD-I). The final steps of gluconeogenesis and glycogenolysis in the
liver require the enzyme glucose-6-phosphatase (G6Pase), whose deficiency causes GSD-I.
Because of this inability, persons with GSD-I often experience severe hypoglycemia and
hepatomegaly (enlarged liver), as well as other metabolic issues.
1-3
There is also a renal form of
GSD (GSD-Ib) that is associated with inflammatory bowel disease and neutropenia, however it is
far less prevalent than the hepatic form (GSD-Ia).
Glycogen Storage Disease Type II (GSD-II), often known as Pompe disease, is another
form of a carbohydrate storage disorder. The inability of lysosomes to break down glycogen due
to a lack of the enzyme acid alpha-glucosidase (GAA) is the root cause of this disease.
2
The
hallmark of Pompe illness is the buildup of glycogen in different body tissues, with the heart and
3
muscles exhibiting an exceptionally high quantity.
2
Respiratory problems, muscle weakness, and
cardiomegaly (enlarged heart) might result from this glycogen accumulation.
Biochemical Basis and Mechanisms
Mutations in the G6PC gene, which codes for glucose-6-phosphatase, are the leading
cause of GSD-I. The enzyme is essential for the liver's ability to release glucose into the
bloodstream as needed because it converts glucose-6-phosphate into glucose.
2
G6Pase deficiency
or dysfunction impairs glucose synthesis in people with GSD-I, resulting in repeated
hypoglycemic episodes.
2
Furthermore, the incapacity to convert surplus glucose to glycogen
leads to the buildup of glycogen in the liver, which can culminate in hepatomegaly, an enlarged
liver that can cause severe abdominal pain and, in certain situations, cirrhosis.
2-3
Moreover, these
GSD-I disturbances impact lipid metabolism, leading to hypertriglyceridemia.
Mutations in the GAA gene cause GSD-II, sometimes referred to as Pompe disease,
which is characterized by an insufficiency of the acid alpha-glucosidase (GAA) enzyme. This
shortage causes glycogen to build up, mostly in lysosomes, where it is stored as lysosomal
glycogen.
2
Glycogen gradually accumulates inside lysosomes, interfering with their regular
activity and resulting in cellular damage. Particularly impacted in Pompe illness, muscle cells
experience gradual weakening and atrophy.
2
The heart, as a muscular organ, is also affected,
potentially leading to cardiomegaly—an enlarged heart and associated cardiac complications.
The age of onset and symptom severity can vary, with early-onset infantile Pompe disease being
the most severe form.
Drug Targets and Therapeutic Interventions
The primary approach to managing GSD-I involves a combination of dietary and
pharmacological interventions. Individuals with GSD-I struggle to maintain normal blood
glucose levels between meals, necessitating frequent carbohydrate feedings.
3
Uncooked
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help
4
cornstarch, a complex carbohydrate, is often employed due to its slow digestion, providing a
sustained release of glucose. Additionally, the administration of the drug allopurinol, which
reduces uric acid production, and angiotensin-converting enzyme (ACE) inhibitors, employed to
manage hypertension, are common practices.
4
Nevertheless, gene therapy has shown significant
promise in preclinical studies as the most hopeful treatment for GSD-I, with the goal of replacing
the deficient G6Pase enzyme.
In the treatment of Pompe disease, recent years have witnessed noteworthy
advancements, particularly with the emergence of enzyme replacement therapy (ERT). ERT
entails intravenous infusions of recombinant human acid alpha-glucosidase (rhGAA), the
enzyme lacking in Pompe disease.
5
This therapy has demonstrated remarkable results in
enhancing muscle function and cardiac outcomes among affected individuals. Another
encouraging avenue is gene therapy, which explores the introduction of a functional GAA gene
into affected cells, allowing them to produce the missing enzyme.
5
Clinical trials have yielded
promising results in enhancing muscle strength and respiratory function.
In summary, carbohydrate storage disorders, typified by Glycogen Storage Disease Type I
and Pompe disease, present intricate metabolic challenges. While GSD-I management includes
dietary measures, supportive drugs, and the promising avenue of gene therapy, Pompe disease
has made significant strides with enzyme replacement therapy and ongoing gene therapy
investigations. These advancements offer hope to patients and their families, highlighting the
potential for improved treatments and a brighter future for those affected by these rare metabolic
conditions. Continued research is poised to further enrich our comprehension and handling of
these disorders, ultimately enhancing the quality of life for individuals living with them.
5
References
1.
Yeo M, Moawad H, Grunewald S. Disorders of carbohydrate metabolism: a review of
glycogen storage disorders.
Paediatrics and Child Health
. Published online January 9, 2023.
doi:
https://doi.org/10.1016/j.paed.2022.12.007
2.
Ellingwood SS, Cheng A. Biochemical and Clinical Aspects of Glycogen Storage
Diseases.
The
Journal
of
endocrinology
.
2018;238(3):R131-R141.
doi:
https://doi.org/10.1530/JOE-18-0120
3.
Rossi A, Ruoppolo M, Formisano P, et al. Insulin-resistance in glycogen storage disease type
Ia: linking carbohydrates and mitochondria?
Journal of Inherited Metabolic Disease
.
2018;41(6):985-995. doi:
https://doi.org/10.1007/s10545-018-0149-4
4.
Derks TGJ, Rodriguez-Buritica DF, Ahmad A, de Boer F, Couce ML, Grünert SC, Labrune P,
López Maldonado N, Fischinger Moura de Souza C, Riba-Wolman R, et al. Glycogen
Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs.
Nutrients
.
2021; 13(11):3828.
https://doi.org/10.3390/nu13113828
5.
Garbade, S.F., Ederer, V., Burgard, P.
et al.
Impact of glycogen storage disease type I on adult
daily life: a survey.
Orphanet J Rare Dis
16
, 371 (2021).
https://doi.org/10.1186/s13023-021-
02006-w